ArticleCancer science2009
Dkk-3 expression in the tumor endothelium: a novel prognostic marker of pancreatic adenocarcinomas.
Article in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2016Pooled it
- Article
- Targeting Wnt Signaling in Endometrial Cancer.Cancers · 2021Review
- Serum dickkopf-3 is associated with death and vascular events after ischemic stroke: an observational study from CATIS.Journal of neuroinflammation · 2020Observational
- Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.Oncogene · 2018Article
- The clinicopathological and prognostic significances of Dkk3 expression in cancers: A bioinformatics analysis.Cancer biomarkers : section A of Disease markers · 2018Article
- Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO.Frontiers in physiology · 2018Review
- Dkk-3 as a potential biomarker for diagnosis and prognosis of colorectal cancer.Medical journal of the Islamic Republic of Iran · 2018Article
- A Cytokine-Like Protein Dickkopf-Related Protein 3 Is Atheroprotective.Circulation · 2017Article
- Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis.Journal of skin cancer · 2017Review
- Aberrant loss of dickkopf-3 in gastric cancer: can it predict lymph node metastasis preoperatively?World journal of surgery · 2015Article
- Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.The Prostate · 2013Article
- Upregulated microRNA-92b regulates the differentiation and proliferation of EpCAM-positive fetal liver cells by targeting C/EBPß.PloS one · 2013Article
- Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.Gynecologic oncology · 2012Article
- Secreted proteins as a fundamental source for biomarker discovery.Proteomics · 2012Review
- Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.World journal of gastroenterology · 2011Article
- Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer.Journal of cancer research and clinical oncology · 2011Article
- HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.British journal of cancer · 2011Article
- Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.International journal of molecular sciences · 2011Review
- Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer.Virchows Archiv : an international journal of pathology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dkk-3 is proposed to be a new specific marker for tumor endothelial cells. Here we analyzed the clinical relevance of Dkk-3 expression in pancreas adenocarcinomas and determined its role on endothelial cell growth in vitro. Microvessel density in tumor samples was immunohistochemically determined using Dkk-3 and CD31 as endothelial cell markers, respectively. Based on the median microvessel density as a cut-off point, patients were categorized into high and low microvessel density groups and a correlation with survival and clinical parameters was assessed. Moreover, the role of Dkk-3 expression on chemosensitivity of endothelial cells was analyzed. In contrast to CD31 staining, Dkk-3-positive vessels were found only in tumor tissue and Dkk-3 microvessel density significantly correlated negative with tumor grading. In survival analysis the median survival time was 7 months for patients with Dkk-3 low, and 15 months for Dkk-3 high microvessel density (P = 0.0013). Subset analysis of patients receiving gemcitabine therapy showed that overall survival was significantly decreased in Dkk-3 low tumors than in high tumors (P = 0.009). In Cox regression Dkk-3 emerged as a significant independent parameter (P = 0.024). Dkk-3 overexpression in endothelial cells resulted in significantly enhanced growth inhibition after 5-fluorouracil or gemcitabine treatment compared to control endothelial cells and cancer cell lines. Dkk-3 low microvessel density was associated with tumor progression and worse clinical outcome. Overexpression of Dkk-3 enhanced endothelial cell growth inhibition to chemotherapeutic drugs. Therefore, we suggest that Dkk-3 high microvessel density may help to select patients who may benefit from chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.